Immediate Impact

55 standout
Sub-graph 1 of 24

Citing Papers

Integration of AIEgens into covalent organic frameworks for pyroptosis and ferroptosis primed cancer immunotherapy
2023 Standout
Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses
2023 Standout
1 intermediate paper

Works of Joel Wallace being referenced

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
2022

Author Peers

Author Last Decade Papers Cites
Joel Wallace 245 103 150 137 17 777
Sang Mee Lee 115 73 240 71 49 842
Joaquim Fernandes 335 22 122 49 17 888
Hazel Squires 220 113 182 51 51 947
Ayden Tajahmady 79 106 87 39 14 763
Lih‐Wen Mau 104 27 145 113 45 678
Mark Minchin 346 77 191 35 8 832
Ruixuan Jiang 258 59 120 47 37 784
Vinit Nair 180 40 103 33 32 871
Edwin D. Huff 236 85 286 76 15 785
Kathleen Lang 159 153 83 77 33 747

All Works

Loading papers...

Rankless by CCL
2026